Search results

Skip to results

Type

Status

Last updated

Showing 1 to 3 of 3 results for tolvaptan autosomal dominant polycystic kidney disease

  1. Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)

    Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease in adults.

    Technology appraisal guidance
    Published
    28 October 2015
    View recommendations

    Sections for TA358

  2. Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)

    Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.

    Technology appraisal guidance
    Published
    13 July 2022
    View recommendations

    Sections for TA807

  3. Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)

    Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    23 March 2023
    View recommendations

    Sections for TA877